Ergomed Share Discussion Threads

[bermudashorts] 22/5/2017 11:17

Haven't managed to find anything from Cel-Sci yet re. FDA decision on Multikine - perhaps later today?

Timbo/anyone - any thoughts on appointment of N+1 Singer?

[timbo003] 19/5/2017 16:42

Here is the most recent letter from Cel-Sci to their share holders which helps put the comments into context:




and this document provides a useful overall summary

[timbo003] 19/5/2017 15:26

Slide set from last night now available:

[bermudashorts] 19/5/2017 11:22

Thanks Timbo. This trial seems to have been a bit of a nightmare for Cel-SCi - currently approaching the end of an arbitration hearing against the former CRO, InVentiv. They're asking for $50m damages and decision due any time now on that too.

[mfhmfh] 19/5/2017 10:59

Thanks for your feedback

[bermudashorts] 15/5/2017 11:51

Timbo - no won't be attending but would be grateful for any feedback as always. Would also be interested in your opinion of Amryt - have just started having a look at them.

[timbo003] 15/5/2017 11:26

Ergomed are at the Proactiveinvestor event on Thursday evening, so I shall go along to that and report back in due course. Anyone else planning to attend?

[battlebus2] 02/5/2017 09:11

Yes holding up very well, company happy to point out its only a part of the business

[timbo003] 02/5/2017 09:08

A remarkably small fall today considering the Aeterna Zentaris news yesterday. I see that Ergomed are at two London meetings later this month (May 10th and May 18th), I have booked a place for both and will feedback in due course:

[bermudashorts] 01/5/2017 14:11

hxxps://endpts.com/aeterna-zentaris-shares-eviscerated-by-its-latest-late-stage-drug-disaster/

[timbo003] 01/5/2017 13:52

Ouch, poor shareholders have had a torrid time over the last 2 years:




....but at least they are better off than the poor patients.

Survival times in the study seem to be more of less in line with what you might expect for late stage disease (see below):





Uterine Cancer (C54-C55), One-Year Age Standardised Net Survival by Stage, Adults (Ages 15-99 Years), England 2014








From:

[mfhmfh] 01/5/2017 13:21

disappointed today like everyone else, unsure how this will impact our share price

reassuring that at least the chairman bought 100,000 shares at 190p in early April.

[douglas fir] 01/5/2017 13:13

AEterna Zentaris Inc. (USA


Pre-market: 1.45 -1.90 (-56.72%)

[battlebus2] 01/5/2017 12:56

Not the outcome we wanted 🤔

[bermudashorts] 01/5/2017 12:45

Yes very disappointing and not looking good for Aeterna Zentaris. The FDA have already rejected Macrilen once, back in 2014, so this is their second attempt at approval and really does seem to be last chance saloon. Even if the FDA do approve it this time, it's a very small market. According to their own figures AGHD affects just 75,000 over the whole of USA, Canada and Europe.

Most of all of course, what a shame for the patients involved. The survival data given in today's press release show what a poor prognosis these patients have.

[timbo003] 01/5/2017 12:22

Indeed, they are not going to pursue the other oncology indications either, so that leaves Aeterna Zentaris with just one shot at goal in the short term, which doesn't sound particularly exciting:

Macrilen (macimorelin) – Oral ghrelin receptor agonist for assessing Adult Growth Hormone Deficiency (AGHD)

Meanwhile back down to around 170-180 pence /share for Ergomed tomorrow I suspect.

[jamtomorrow2] 01/5/2017 12:10

Zoptrex trial failed. No chance of getting it approved according to AEZS.

[bermudashorts] 30/4/2017 17:14

Thanks jam and timbo. Huge amount riding on these results for Aeterna Zentaris.

[battlebus2] 30/4/2017 16:55

Looking forward to that.

[timbo003] 30/4/2017 16:42

For tomorrow:


Aeterna Zentaris Press release page


Aeterna Zentaris ADVFN quote page

[jamtomorrow2] 29/4/2017 17:39

Zoptrex Phase 111 results to be released by AEZS before 9.30ET on Monday. Someone posted that Ergo's pay-out is capped at £50m. If approved that could eventually be worth 100p per share. Nice.

[bermudashorts] 21/4/2017 18:21

Makes a relaxing change to be looking forward to clinical trial results without the usual degree of risk.

[timbo003] 21/4/2017 17:19

>>>BS

Yes, SS stated in one recent meeting (I cannot remember which one) that results were due this month, so that means next week week. Valuation wise it should shift analyst estimates -40p for a fail and +40p for a successful outcome (approx).

[bermudashorts] 21/4/2017 17:06

N+1 Singer have increased their target for Ergomed from 293 to 360. Zoptrex phase III results due from Aeterna Zentaris any day now.